U.S. Stocks Update: Immunovant plunges on September 23 as CLE trial misses endpoint and project is terminated
Bitget异动解读2026/09/23 14:40Immunovant September 23 Plunge Interpretation
Keywords: CLE trial did not reach endpoint, project termination
1. On September 23, 2026, the proof-of-concept study of IMVT-1402 for the treatment of cutaneous lupus erythematosus failed to achieve statistical significance for the week 12 CLASI-A primary endpoint, weakening clinical development expectations for this indication.
2. On September 23, 2026, due to clinical results and the competitive landscape not meeting the company’s internal standards for continued development, the company decided to terminate the development of IMVT-1402 for the cutaneous lupus erythematosus indication, narrowing the application scope of the candidate drug.
(Disclaimer: This content is summarized and generated based on publicly available information using AI technology and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US weekly EIA strategic petroleum reserve inventory decreased by 405,000 barrels.